Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity.

European journal of heart failure - 1 Oct 2007

Deng Shiwei, Kulle Bettina, Hosseini Mehdi, Schlüter Gregor, Hasenfuss Gerd, Wojnowski Leszek, Schmidt Albrecht

Abstract excerpt

BACKGROUND AND AIM: The clinical use of doxorubicin (DOX) and other anthracyclines is limited by a dosage-dependent cardiotoxicity, which can lead to cardiomyopathy. The role of the individual genetic makeup in this disorder is poorly understood. Alterations in genes encoding cardiac cytoskeleton or sarcolemma proteins may increase the susceptibility to doxorubicin-related cardiotoxicity. METHODS: Female...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Susceptibility

Share to Doxorubicin

Share to Dystrophin

Share to Heart Diseases

Share to Microarray Analysis

Share to Ultrasonography

Source

Identifiers

PMID: 17888722
DOI: 10.1016/j.ejheart.2007.07.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity.PMID 17888722Read ↗

Sex Differences in Doxorubicin‐Induced Cardiotoxicity: Insights from Transcriptome AnalysisSemantic proximity Read ↗

Integrated Omics Approach to Delineate the Mechanisms of Doxorubicin-Induced CardiotoxicitySemantic proximity Read ↗

Transcriptomic Insights into Early Diagnosis of Doxorubicin-Induced Cardiotoxicity in a Rat ModelSemantic proximity Read ↗

Different Mechanisms in Doxorubicin-induced Cardiomyopathy: Impact of BRCA1 and BRCA2 MutationsSemantic proximity Read ↗

Sex differences in cardiomyocyte proteomic responses to the cardiotoxic chemotherapy drug doxorubicinSemantic proximity Read ↗

Anthracycline-mediated cardiomyopathy: Basic molecular knowledge for the cardiologistSemantic proximity Read ↗

Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicitySemantic proximity Read ↗

Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat ModelSemantic proximity Read ↗

Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targetsSemantic proximity Read ↗

A Doxorubicin-induced Cardiomyopathy Model in Adult ZebrafishSemantic proximity Read ↗

Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity?Semantic proximity Read ↗

The anti-cancer drug doxorubicin induces substantial epigenetic changes in cultured cardiomyocytesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.